Skyrizi (risankizumab-rzaa) / AbbVie, Boehringer Ingelheim - LARVOL DELTA

Understanding Psoriasis Patient Preferences for Biologic Dosing Frequencies: Insights From a Patient Survey. (PubMed, J Psoriasis Psoriatic Arthritis) - "This study evaluates patient dosing preferences for IL-17 and IL-23 inhibitors, risankizumab (RZB) every 12 weeks, guselkumab (GUS) every 8 weeks, and ixekizumab (IXE) every 4 weeks, in managing PsO. No statistically significant differences were observed in dosing frequency preference between treatment groups, suggesting dosing schedule is not a primary concern for most patients. This aligns with previous research demonstrating effective disease control is the most important factor for patient satisfaction; however, tailoring dosing regimens to individual patient needs can also strengthen long-term adherence, as demonstrated in recent studies."

Journal • Dermatology • Immunology • Psoriasis • IL17A • IL23A

REVAMP: A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (clinicaltrials.gov) - P3 | N=530 | Recruiting | Sponsor: AbbVie | Not yet recruiting ➔ Recruiting

Enrollment open • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled Syringe or an On-Body Injector in Healthy Adult Participants (clinicaltrials.gov) - P1 | N=252 | Not yet recruiting | Sponsor: AbbVie

New P1 trial

Interleukin-23 Inhibitors for Inflammatory Bowel Disease: Pivotal Trials and Practical Considerations. (PubMed, Curr Gastroenterol Rep) - "IL-23 inhibitors are safe and effective for treatment of moderate-to-severe inflammatory bowel disease and appear more effective than ustekinumab for Crohn's disease. The currently available IL-23 inhibitors likely have similar efficacy, but practical considerations may influence preferences."

Journal • Review • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • IL23A

IXEKIZUMAB OR INTERLEUKIN-23 INHIBITORS IN PATIENTS WITH PSORIATIC ARTHRITIS: KEY REAL-WORLD OUTCOMES FROM THE PROSPECTIVE OBSERVATIONAL PARTUS STUDY IN THE US (EULAR 2025) - "IXE or an IL-23i (guselkumab [GUS] or risankizumab [RZB]) was initiated in accordance with the Food and Drug Administration (FDA) labelling in a US clinical setting. The results from the prospective observational RW study PARTUS showed that patients with active PsA treated with IXE achieved meaningful early improvements by W4 in both disease activity and patient-reported outcomes. Disease outcomes continued to improve up to W12. Patients treated with IXE reached disease activity remission and low disease activity rapidly and through W12."

Clinical • Observational data • Real-world • Real-world evidence • Dermatology • Fatigue • Immunology • Inflammatory Arthritis • Musculoskeletal Diseases • Oncology • Pain • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

SOCIAL MEDIA PERSPECTIVES OF BIOLOGICS AND TARGETED THERAPY IN PSORIATIC ARTHRITIS (EULAR 2025) - "We then narrowed the search to specific treatments using the term ‘psoriatic arthritis’ coupled with ‘adalimumab’, ‘baricitinib’ ‘brodalumab’, ‘certolizumab’, ‘etanercept’, ‘guselkumab’, ‘infliximab’, ‘ixekizumab’, ‘risankizumab’, ‘secukinumab’, ‘tildrakizumab’, ‘tofacitinib’, ‘upadacitinib’, and ‘ustekinumab’ and as well as their respective brand names. Social media perceptions of biologics and targeted therapies are largely positive, however there is significant commentary on downsides including local/systemic adverse effects and lack/loss of efficacy. It is important that physicians in their consultations address these common patient concerns that may be perpetuated by social media."

Immunology • Inflammatory Arthritis • Pain • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL17A

TREATMENT OUTCOME AND PERSISTENCE OF IL-23 INHIBITORS IN A REAL-WORLD COHORT OF PsA PATIENTS - A RETROSPECTIVE STUDY (EULAR 2025) - "Objectives: The primary objective was to evaluate the efficacy and drug survival of two IL-23i Guselkumab and Risankizumab, in a cohort of difficult to treat psoriatic arthritis (PsA) patients, reflecting real-world clinical practice. In this real-world cohort of difficult to treat PsA patients, IL-23i demonstrated a short drug survival time and limited effectiveness in managing joint disease."

Real-world • Real-world evidence • Retrospective data • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL23A

RISANKIZUMAB EFFICACY IN MALE AND FEMALE PATIENTS WITH PsA: A POOLED ANALYSIS OF KEEPsAKE 1 AND 2 TRIALS (EULAR 2025) - "Males and females show a generally consistent response to RZB up to w 148. In line with published available data for other drugs used to treat PsA, males are more likely to achieve MDA and resolution of enthesitis possibly due to a lower disease burden compared to females at baseline. RZB is effective for PsA in both males and females compared to PBO."

Retrospective data • Dermatology • Fatigue • Immunology • Inflammatory Arthritis • Pain • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A • IL23A • TYK2

REAL-WORLD EFFECTIVENESS AND SATISFACTION IN BIOLOGIC-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS AND LIMITED JOINT INVOLVEMENT TREATED WITH RISANKIZUMAB IN THE UNITED STATES AND EUROPE (EULAR 2025) - "In biologic-naïve patients with PsA and limited joint involvement or oligoarthritis, RZB treatment resulted in significant and clinically meaningful improvements in peripheral joint involvement, pain, and fatigue in real-world clinical practice. Both patients and physicians reported high levels of satisfaction with RZB as a treatment for managing disease in biologic-naïve PsA."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Ankylosing Spondylitis • Dermatology • Fatigue • Immunology • Inflammatory Arthritis • Pain • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis

HEAD-TO-HEAD STUDY OF BIMEKIZUMAB, AN IL-17A/IL-17F INHIBITOR, AND RISANKIZUMAB, AN IL-23 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: STUDY DESIGN AND RATIONALE OF BE BOLD, A PHASE 3B, RANDOMISED, PARALLEL-GROUP STUDY (EULAR 2025) - "BE BOLD is the first head-to-head study to evaluate efficacy and safety of an IL-17A/IL-17F inhibitor vs an IL-23 inhibitor in patients with active PsA; testing for superiority of bimekizumab over risankizumab in joint disease, using the primary endpoint of ACR50 at Week 16."

Clinical • Head-to-Head • P3 data • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A • IL23A

LOW INCIDENCE OF NEONATAL INFECTION WITH TNF AND NON-TNF BIOLOGIC DMARD USE IN THE SECOND AND THIRD TRIMESTERS OF PREGNANCY (EULAR 2025) - "Patients were treated with the following biologics in pregnancy: 27 were on certolizumab, 17 were on adalimumab, 13 were on etanercept (including one in combination with risankizumab), 9 were on infliximab, 3 were on secukinumab, 3 were on golimumab, 2 were on rituximab and 1 was on anakinra. In this single center study, the late exposure to biologics in pregnancy yielded a very low incidence of infection in newborns to mothers with autoimmune conditions. The results of this study support the most recent 2024 EULAR Update in taking a more permissive approach to the continuation of biologics in pregnancy for the treatment of autoimmune diseases."

Ankylosing Spondylitis • Crohn's disease • Dermatology • Gastroenterology • Hematological Disorders • Idiopathic Arthritis • Immunology • Infectious Disease • Inflammatory Arthritis • Inflammatory Bowel Disease • Obstetrics • Pneumonia • Psoriasis • Psoriatic Arthritis • Respiratory Diseases • Respiratory Syncytial Virus Infections • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Real-World Switching Patterns for Patients with Psoriatic Arthritis on First-Line Advanced Therapies (EULAR 2025) - "Switching was evaluated for the overall population, stratified by the mechanism of action (MOA; reference IL-23i) and individual drugs (reference: risankizumab (RZB))...RZB was associated with significantly lower proportion of switchers (3.8%) than guselkumab (12.9%), followed by secukinumab (18.8%), ixekizumab (20.8%), apremilast (26.9%), etanercept (30.0%) and adalimumab (32.4%) (all P<0.05)... The proportion of PsA patients taking 1LAT who switched over 12 months was the lowest with IL-23i. At the individual drug level, RZB was associated with the lowest odds of switching."

Clinical • Metastases • Real-world • Real-world evidence • Immunology • Inflammatory Arthritis • Oncology • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL17A

Real-World Effectiveness and Satisfaction With Risankizumab for the Treatment of Early Psoriatic Arthritis in Biologic-Naïve Patients: A Population Survey in the United States and Europe (EULAR 2025) - "In real-world clinical settings, biologic-naïve patients with early PsA who initiated RZB treatment demonstrated significant and clinically meaningful improvements in peripheral joint involvement, pain, and fatigue. Both patients and physicians reported high levels of satisfaction with RZB as an effective treatment for disease control in biologic-naïve PsA."

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Ankylosing Spondylitis • Dermatology • Fatigue • Immunology • Inflammatory Arthritis • Pain • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis

Myocardial infarction, stroke, venous thromboembolic events, serious infections and malignancy in patients with psoriatic arthritis treated with tofacitinib compared to biologic treatments in the United States (EULAR 2025) - " Pts with PsA aged ≥18 years newly initiating tofacitinib or a biologic (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab [tumour necrosis factor inhibitors (TNFi)]; secukinumab/ixekizumab [interleukin-17 inhibitors (IL-17i)]; risankizumab or ustekinumab) from 15 December 2017–30 September 2022, with ≥12 months of continuous enrolment prior to the index date (date of PsA therapy initiation) were included. In this US claims dataset, there were no significant differences in risk of developing MI/stroke, serious infections or malignancy for tofacitinib vs biologics, among PsA pts not enriched for cardiovascular/VTE risk factors. A decreased risk of VTE with TNFi vs tofacitinib was found, aligning with previous clinical trial data. Limitations included the variable numbers of safety events across treatments and potential uncontrolled confounding of VTE-specific risk factors, such as surgery."

Clinical • Cardiovascular • Dermatology • Dermatopathology • Genetic Disorders • Immunology • Infectious Disease • Inflammatory Arthritis • Myocardial Infarction • Oncology • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Skin Cancer • Solid Tumor • IL17A

Time to First Clinically Meaningful Efficacy Responses in Musculoskeletal and Patient Reported Outcomes in Patients With Active Psoriatic Arthritis Treated With Risankizumab: A Post Hoc Analysis of the Phase 3 KEEPsAKE 1 and KEEPsAKE 2 Trials (EULAR 2025) - P3 | "This post hoc analysis of the median time to first response in key MSK responses and PROs demonstrates early median time to clinically meaningful efficacy for patients with PsA treated with RZB, with related improvement in quality of life."

Clinical • P3 data • Patient reported outcomes • Retrospective data • Fatigue • Immunology • Inflammatory Arthritis • Musculoskeletal Diseases • Pain • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Factors Associated with Response to IL23 Inhibitors in Axial and/or Mixed Psoriatic Arthritis: A Multicenter Observational Study (APxis-IL23) (EULAR 2025) - "Objectives: To identify factors associated with clinical response to guselkumab (GUS) and risankizumab (RSK) in patients with axial and/or mixed PsA in real-world clinical practice. In our real-world clinical experience, GUS and RSK may be therapeutic options for patients with axial and/or mixed PsA, particularly those meeting ASAS axial SpA criteria and with baseline ASDAS-CRP >2.1. These findings highlight the importance of patient stratification to optimize management of axial PsA."

Clinical • Observational data • Ankylosing Spondylitis • Genetic Disorders • Immunology • Inflammatory Arthritis • Obesity • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis

Combination of Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis (EULAR 2025) - "One patient experienced two mild upper respiratory infections (URIs) on bimekizumab and deucravacitinib, prompting a switch for risankizumab with deucravacitinib...We also identified 15 patients treated with bDMARDs combined with apremilast (APR) for a median duration of 735 days... Overall, the safety profile of bDMARD combinations with JAKi, TYK2i, and APR was favorable. Infections, primarily URIs, were the most commonly observed adverse events. All reported infections were mild, managed without hospitalization, and rarely led to therapy discontinuation."

Dental Disorders • Dermatology • Immunology • Infectious Disease • Inflammatory Arthritis • Musculoskeletal Diseases • Pain • Psoriasis • Psoriatic Arthritis • Respiratory Diseases • Rheumatology • Seronegative Spondyloarthropathies • Stomatitis • IL12A • IL17A

Guselkumab (Tremfya) - an IL-23 antagonist for Crohn's disease. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease • IL23A

Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Participants With Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis (clinicaltrials.gov) - P=N/A | N=2324 | Active, not recruiting | Sponsor: AbbVie | Recruiting ➔ Active, not recruiting

Enrollment closed • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

The effect of IL-17 and IL-23 ınhibitors on hematological ınflammatory parameters in patients with psoriasis vulgaris. (PubMed, Ir J Med Sci) - "The significant reduction in NLR and SII levels in both the IL-17 and IL-23 groups suggests that these markers may be used together rather than separately in treatment follow-up. The significant decrease in PHR levels may indicate that IL-17 and IL-23 inhibitors contribute to reducing cardiovascular disease risk in patients with psoriasis vulgaris and promote a favorable long-term prognosis."

Journal • Cardiovascular • Dermatology • Hematological Disorders • Immunology • Inflammation • Psoriasis • IL17A • IL23A

DMARDs and biologics are protective against alopecia areata in psoriasis patients (SID 2025) - "DMARDs analyzed included methotrexate, cyclosporine, apremilast. Biologic therapies included TNF-alpha inhibitors (adalimumab, etanercept, infliximab, certolizumab pegol, golimumab), IL-17 inhibitors (brodalumab, ixekizumab, secukinumab, bimekizumab), and IL-12/23 and IL-23 inhibitors (ustekinumab, guselkumab, risankizumab, tildrakizumab)...IL-17 inhibitors (n=7, 670) were associated with a non-significant decrease in risk (RR: 0.909; 95% CI: 0.386-2.138). These findings demonstrate the protective nature of DMARDS and biologics, particularly TNF-alpha, IL-12/23, and IL-23 inhibitors, against AA in PsO patients, highlighting the need for further research into shared mechanisms of disease underlying PsO and AA."

Clinical • Alopecia • Dermatology • Genetic Disorders • Immunology • Inflammation • Obesity • Psoriasis • IL12A • IL17A • IL23A

Systematic review of comparative studies on emerging psoriasis treatments: comparing biologics with biologics, small molecule inhibitors with small molecule inhibitors, and biologics with small molecule inhibitors. (PubMed, Inflammopharmacology) - "This systematic review highlights the enhanced efficacy of IL-17 and IL-23 inhibitors compared to TNF-α inhibitors, with IL-23-targeting agents demonstrating superior long-term disease control. Small molecule inhibitors, particularly Deucravacitinib, present a promising alternative as effective oral therapies. Although newer biologics offer improved treatment outcomes, further head-to-head trials comparing TYK2, JAK, and PDE4 inhibitors with IL-17 and IL-23 agents are warranted. These findings provide valuable insights to inform clinical decision-making and optimise Psoriasis management strategies."

Journal • Review • Candidiasis • Dermatology • Immunology • Infectious Disease • Psoriasis • IL17A • IL23A • TYK2

Drug survival of IL-23 and IL-17 inhibitors versus other biologics for psoriasis: A British Association of Dermatologists Biologics and Immunomodulators Register cohort study. (PubMed, J Eur Acad Dermatol Venereol) - "Guselkumab and risankizumab have the most favourable drug survival for effectiveness, with comparable safety to ustekinumab, and more favourable than other BADBIR biologics. Longer drug survival may reduce treatment burden by minimizing treatment switches, clinic visits and disease flares, supporting IL-23p19 inhibitors as a practical long-term option for psoriasis."

Journal • Dermatology • Immunology • Inflammatory Arthritis • Oncology • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL17A • IL23A

Optimizing Biologic Therapy for the Prevention of Post-Operative Recurrence in Crohn's Disease: Current Evidence and Future Perspectives. (PubMed, Biomedicines) - "Conventional management relies on early prophylactic therapy with anti-TNF agents such as infliximab and adalimumab, which have demonstrated efficacy in reducing endoscopic and clinical recurrence. However, newer biologics, including IL-23 inhibitors (risankizumab) and Janus kinase (JAK) inhibitors (upadacitinib), have shown promise in CD management, though their role in POR remains underexplored...Future directions should focus on optimizing therapeutic strategies through personalized medicine, identifying predictive biomarkers, and conducting robust trials to establish the efficacy of novel agents in POR prevention. A tailored, evidence-driven approach is essential to improving long-term outcomes and minimizing disease recurrence in post-operative CD patients."

Journal • Review • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease • IL23A

Emerging Therapies for Palmoplantar Pustulosis with a Focus on IL-23 Inhibitors. (PubMed, J Clin Med) - "Notably, guselkumab and risankizumab have recently been approved for PPP treatment in Japan and Korea...A recent phase 3 trial in Japan demonstrated the significant efficacy of apremilast in treating PPP, with a favorable safety profile, suggesting that apremilast may be a promising treatment option for PPP...Further large-scale, controlled studies are needed to clarify the efficacy and long-term safety of these therapies in diverse populations. This review summarizes emerging evidence on IL-23 inhibitors and other treatments for PPP, detailing their mechanisms of action, clinical efficacy, safety profiles, current challenges, and future perspectives in optimizing therapy."

Journal • Review • Dermatology • Immunology • Inflammation • Psoriasis • IL17A • IL23A